Skip to main content

Table 7 Impact of SmfD and mfAC levels up to the relevant timepoint on mfAC levels pre-treatment and at different timepoints post-treatment

From: Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

mfAC at time

Covariates in the final model

p value ≤ 0.05

p value > 0.5

PreTx

SmfD preTx

 < 0.0001

 

Day 4

SmfD preTx

0.0006

 
 

mfAC preTx

 < 0.0001

 

Month 1

SmfD preTx

 < 0.0001

 
 

SmfD Month 1

0.0058

 
 

mfAC preTx

 

0.1469

 

mfAC Day 4

 < 0.0001

 

Month 6

SmfD preTx

 

0.9828

 

SmfD Month 1

0.0002

 
 

SmfD Month 6

 

0.1561

 

mfAC preTx

 

0.6150

 

mfAC Day 4

0.0419

 
 

mfAC Month 1

 < 0.0001

 

Month 12

SmfD preTx

0.0015

 
 

SmfD Month 1

 

0.0544

 

SmfD Month 6

 

0.8066

 

SmfD Month 12

0.001

 
 

mfAC preTx

0.0015

 
 

mfAC Day 4

 

0.2651

 

mfAC Month 1

 < 0.0001

 
 

mfAC Month 6

 < 0.0001

 

Month 18

SmfD preTx

 

0.1763

 

SmfD Month 1

 

0.9814

 

SmfD Month 6

 

0.3455

 

SmfD Month 12

 

0.2232

 

SmfD Month 18

 

0.7997

 

mfAC preTx

 

0.2282

 

mfAC Day 4

 

0.6282

 

mfAC Month 1

 

0.8748

 

mfAC Month 6

0.0001

 
 

mfAC Month 12

 < 0.0001

 
  1. mfAC: live microfilariae in the anterior chambers; SmfD: skin microfilariae density (microfilariae/mg skin)